Physicians’ attitude towards selection of second line therapy with nilotinib and dasatinib in chronic myeloid leukemia patients
Crossref DOI link: https://doi.org/10.1186/s12955-017-0788-4
Published Online: 2017-10-18
Published Print: 2017-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Breccia, Massimo
Baccarani, Michele
Rosti, Gianantonio
Cottone, Francesco
Cannella, Laura
Guilhot, François
Vignetti, Marco
Efficace, Fabio